ACTRN12613000058774招募中4 期
Mitotane Pharmacodynamics in Adrenocortical Cancer in Children and Adults
适应症
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- Years 至 100 Years（—）
- 性别
- All
入选标准
- •1. Adrenocortical carcinoma, any stage.
- •2. Treating physician is of the opinion that Mitotane therapy is indicated for the patient
- •3. Normal haematological parameters
- •4. Normal liver function
- •5. Adequate renal function
- •6. Eastern Co-operative Oncology Group (ECOG) performance status 0-2 .
- •7. No other significant medical illness.
- •8. Geographically accessible and physically capable of completing study investigations as required.
- •9. Informed consent for study investigations.
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
Evaluation of Side Effects of MitotaneAdrenocortical CarcinomaNCT00568139University of Wuerzburg400
已完成
3 期
Adjuvant Chemotherapy vs. Observation/Mitotane After Primary Surgical Resection of Localized Adrenocortical CarcInomaAdrenocortical CarcinomaNCT03723941Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia40
进行中（未招募）
1 期
Treatment strategy in adrenocortical carcinomasFase II trial with docetaxel and cisplatin in patients with locally advanced or disseminated adrenocortical carcinomasEUCTR2005-001341-42-DKRigshospitalet39
已完成
不适用
Pharmacogenetics of Mitotaneadrenal canceradrenal neoplasm10001353NL-OMON42303Maxima Medisch Centrum50
Unknown
3 期
Efficacy of Adjuvant Mitotane Treatment (ADIUVO)Adrenocortical CarcinomaNCT00777244University of Turin, Italy200